Key points are not available for this paper at this time.
Graft-v-host disease (GVHD) is the clinicopathologic syndrome that results from the reaction initiated by a "graft" of immunologically competent lymphocytes introduced into a "host" that confronts the graft with a histocompatibility difference, but is unable to mount an immunologic attack against the donor lymphoid cells. Although GVHD is most commonly recognized as a complication of allogeneic marrow transplantation, GVHD has also been reported following transfusion of nonirradiated blood products to patients with compromised immunologic function. Graft-v-host disease has been described in neonates who received intrauterine or exchange transfusions for hemolytic disease of the newborn,1in children with congenital immune deficiency or progressive vaccinia necrosum who were given fresh plasma or blood,2in patients with leukemia or lymphoma who were given granulocyte transfusions,3,4and in patients with neuroblastoma5or Hodgkin's disease6who were given transfusions of packed RBCs only. Typically, a seemingly
Paul L. Weiden (Wed,) studied this question.